WO2007116428A8 - Composition pharmaceutique orale contenant de la cystine ou de la cysteine associee a de la glutathione pour la prevention et le traitement du stress oxydant resultant de l'hemodialyse, et dispositif medical pour l'administration de ladite composition - Google Patents

Composition pharmaceutique orale contenant de la cystine ou de la cysteine associee a de la glutathione pour la prevention et le traitement du stress oxydant resultant de l'hemodialyse, et dispositif medical pour l'administration de ladite composition

Info

Publication number
WO2007116428A8
WO2007116428A8 PCT/IT2007/000261 IT2007000261W WO2007116428A8 WO 2007116428 A8 WO2007116428 A8 WO 2007116428A8 IT 2007000261 W IT2007000261 W IT 2007000261W WO 2007116428 A8 WO2007116428 A8 WO 2007116428A8
Authority
WO
WIPO (PCT)
Prior art keywords
cysteine
haemodialysis
pharmaceutical composition
composition containing
oxidative stress
Prior art date
Application number
PCT/IT2007/000261
Other languages
English (en)
Other versions
WO2007116428A3 (fr
WO2007116428A2 (fr
Inventor
Francesco Santangelo
Francesco Paolo Pilato
Original Assignee
Bio3 Res Srl
Francesco Santangelo
Francesco Paolo Pilato
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio3 Res Srl, Francesco Santangelo, Francesco Paolo Pilato filed Critical Bio3 Res Srl
Priority to MX2008012974A priority Critical patent/MX2008012974A/es
Publication of WO2007116428A2 publication Critical patent/WO2007116428A2/fr
Publication of WO2007116428A8 publication Critical patent/WO2007116428A8/fr
Publication of WO2007116428A3 publication Critical patent/WO2007116428A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique orale contenant de la cystine ou de la cystéine associée à de la glutathione, pour la prévention et le traitement du stress oxydant résultant de l'hémodialyse chez les patients présentant une insuffisance rénale chronique.
PCT/IT2007/000261 2006-04-10 2007-04-06 Composition pharmaceutique orale contenant de la cystine ou de la cysteine associee a de la glutathione pour la prevention et le traitement du stress oxydant resultant de l'hemodialyse, et dispositif medical pour l'administration de ladite composition WO2007116428A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2008012974A MX2008012974A (es) 2006-04-10 2007-04-06 Composicion farmaceutica oral que contiene cistina o cisteina con glutationa, para la prevencion y el tratamiento de tension oxidante originada por hemodialisis, y dispositivo medico para su administracion.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2006A000206 2006-04-10
IT000206A ITRM20060206A1 (it) 2006-04-10 2006-04-10 Composizione farmaceutica orale contenente cistina o cisteina con glutatione per la prevenzione ed il trattamento dello stress ossidativo da emodialisi e dispositivo medico di somministrazione

Publications (3)

Publication Number Publication Date
WO2007116428A2 WO2007116428A2 (fr) 2007-10-18
WO2007116428A8 true WO2007116428A8 (fr) 2007-12-13
WO2007116428A3 WO2007116428A3 (fr) 2008-03-13

Family

ID=38480485

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2007/000261 WO2007116428A2 (fr) 2006-04-10 2007-04-06 Composition pharmaceutique orale contenant de la cystine ou de la cysteine associee a de la glutathione pour la prevention et le traitement du stress oxydant resultant de l'hemodialyse, et dispositif medical pour l'administration de ladite composition

Country Status (4)

Country Link
KR (1) KR20090024673A (fr)
IT (1) ITRM20060206A1 (fr)
MX (1) MX2008012974A (fr)
WO (1) WO2007116428A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2527802B (en) * 2014-07-02 2019-10-16 Olimed Ltd An orally disintegrating tablet with differentiated absorption
FR3092491B1 (fr) * 2019-02-11 2021-11-12 Bretagne Chimie Fine Utilisation non-thérapeutique par voie orale d’une composition pour blanchir et/ou éclaircir la peau comprenant de la cystine et du glutathion dans un rapport cystine/glutathion allant de 1,5 à 4

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146265B1 (fr) * 1983-11-15 1991-04-03 Kyowa Hakko Kogyo Co., Ltd. Procédé de production d'un composé à partir de son précurseur en utilisant l'activité enzymatique d'une bactérie
US5576287A (en) * 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
US6228347B1 (en) * 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
KR100390630B1 (ko) * 1999-07-02 2003-07-07 이희발 항 산화제를 함유한 복막투석액
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il

Also Published As

Publication number Publication date
WO2007116428A3 (fr) 2008-03-13
WO2007116428A2 (fr) 2007-10-18
MX2008012974A (es) 2008-12-18
ITRM20060206A1 (it) 2007-10-11
KR20090024673A (ko) 2009-03-09

Similar Documents

Publication Publication Date Title
AU2018260815A1 (en) Treatment of Acute Lymphoblastic Leukemia
EA201100958A1 (ru) Фармацевтическая пероральная дозированная лекарственная форма на основе ингибиторов dpp iv
IL219915A0 (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
MY148723A (en) Use of pinolenic acid for the treatment of obesity
EA201200968A1 (ru) Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин
WO2005077103A3 (fr) Compositions et methodes de modification et de prevention de l'infectiosite du coronavirus du sras
NZ594814A (en) Peptide that is derived from a milk protein and has an antioxidative effect and also acts as a blood adiponectin level increase promotion and/or decrease inhibition agent
WO2008022974A3 (fr) Composition antidiabetique contenant de l'acide chicorique et/ou l'un de ses metabolites
TW200700071A (en) Novel use
WO2008046865A3 (fr) Système d'alimentation à long terme pour personnes agées
WO2008017752A3 (fr) Extrait d ' eucalyptus, son procede de preparation et ses utilisations therapeutiques
WO2009068708A3 (fr) Composition pharmaceutique à libération prolongée de somatostatine ou d'un analogue de celle-ci
WO2008008882A3 (fr) Modulateur du récepteur des glucocorticoïdes et procédés d'utilisation
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
EP1843781A4 (fr) Composition pour la prevention, le traitement et le diagnostic de maladies chroniques inflammatoires des voies aeriennes
WO2007116428A3 (fr) Composition pharmaceutique orale contenant de la cystine ou de la cysteine associee a de la glutathione pour la prevention et le traitement du stress oxydant resultant de l'hemodialyse, et dispositif medical pour l'administration de ladite composition
EP2193789B8 (fr) Utilisation du 5-methyl-1,3-benzenediol ou de ses derives dans la preparation de medicaments ou de nourriture fonctionnelle destines au traitement ou a la prevention de la depression
EA200801890A1 (ru) Средство для лечения шума в ушах
EP1997503A3 (fr) Traitement de la mélanome avec peptides de thymosine alpha
EA200970877A1 (ru) Композиция, пригодная для предупреждения диабета 2 типа и его осложнений у пациентов с предиабетом с резистентностью к инсулину
WO2007116297A3 (fr) Utilisation d'aminaphtone pour la préparation d'un médicament destiné au traitement d'artériopathies
ZA200705349B (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
WO2008121006A8 (fr) Administration de sélénium
EA201000738A1 (ru) Медицинское применение 3-(2,2,2-триметилгидразиниум)пропионат гидрофумарата и дигидрофосфата
WO2007054566A3 (fr) Utilisation du fenofibrate ou d'un de ses derives pour la prevention de la retinopathie diabetique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07736765

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/012974

Country of ref document: MX

Ref document number: 4082/KOLNP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020087027326

Country of ref document: KR

122 Ep: pct application non-entry in european phase

Ref document number: 07736765

Country of ref document: EP

Kind code of ref document: A2